- Joined
- 13 February 2006
- Posts
- 5,698
- Reactions
- 13,896
Health care stocks are experiencing one of their worst streaks of underperformance in history. With policy uncertainty under RFK, industry-wide cost pressures, and an insurance sector crisis... these stocks haven't been able to get on trend with the broader market. In fact, they've barely participated this entire cycle. In early May, the 4-week relative rate of change hit -13%, its lowest reading of all time. Health care stocks had never done so poorly over a trailing one-month basis. Extreme momentum readings like this tend to show up at turning points in the trend. So the question is simple… Was the collapse in healthcare a sign of exhaustion or initiation? |
In other words, is this blowout downside momentum signaling the end of an old downtrend… or the beginning of a new one? And I think it's pretty obvious we’re looking at exhaustion here. It simply can’t be the initiation of a new downtrend. XLV/SPY has been moving in a straight line lower for the last two and a half years. It’s already in a downtrend! So I’ve been picking my spots and buying large-cap healthcare stocks in the long-term account... preparing for a sustained rotation. Let’s start with Merck $MRK. |
I think this massive dot-com bubble base finally resolves higher in the future, and I’m using the tactical reversal pattern that’s playing out right now to get a prime entry. The dividend here is great so I plan to sit back and collect my 4% while I wait for this pharma leader to break out. Pfizer is also working on a tactical base and pays a sky-high 6.7% yield. Here’s a zoomed-in look at Pfizer $PFE: |
If we can clear and hold 26, Pfizer is headed back into the 30s. One of my favorites in health care right now is Medtronic $MDT. |
This is the best-looking fresh primary trend reversal in the sector. If we’re above 92, I’m long MDT with an initial target of 110 and secondary objective of 135. Next let’s look at some leaders. I think this monster base in GILD is about to resolve and I’m jumping it using the VWAP from the pivot highs. |
We'll get confirmation this breakout is in the books above 123. From there, the first stop is 164. Next is BSX which has completely ignored the broad weakness in health care this cycle. This has been one of the best ones to own up until now and I think that only continues if the overall sector finds its footing. |
I like BSX above 110 with a target of 175. The stock reported an earnings beat and gapped to fresh all-time highs Wednesday. Another green candle or two will break this leader back out. Last but not least, I came across a handful of potential failed tops in the sector. First up, here’s Thermo Fisher $TMO. |
The hook is already in for TMO. As long as we're above 430, this top is failing. I'm long with a target back toward the old highs around 620. And I feel the same way about Danaher $DHR. |
It looks poised to trap the bears and scoop higher in similar fashion to TMO. I plan to buy it on strength above 207 in the coming days and weeks. While we’re at it, industry leader and largest XLV component Eli Lilly is unlikely to complete its massive top too. Especially if the broader space is just getting going. So that bodes well for XLV itself as LLY will continue to be a primary driver of performance. The bottom line is I’m expecting there to be more and more bullish opportunities in this battered sector in the future. I think the bottom is in. For now, I like the idea of adding some quality exposure with these large cap anchor positions. |
The issue with XLV components is that Trump has via Medicare reforms, killed their profitability.

This week the WSJ reported that the US burned through nearly 25% of all the THAAD air defense missiles it had ever purchased in just 12 days of medium-intensity combat against a non-peer adversary (Iran.) The second derivative implications of this story are enormous: It is proof that the US has outsourced too much of its defense industrial base, a strategic mistake that will likely be attempted to be rectified aggressively in coming years. What does this mean for macro?
The offshoring of the US defense industrial base was disinflationary, good for the real value of LT USTs, and good for Washington DC, Wall Street, and China relative to US working class wages and US industrial output.
Reverse all of those for what the macro impacts of reshoring will likely be(inflationary, bad for real value of LT USTs, and bad for Washington DC, Wall Street, and China relative to US working class wages and US industrial output.)
- The Dow Jones Industrial Average closed just 10 points shy of an all-time high, or -0.02% on a weekly closing basis. However, it still gained +1.3% this week.
- The other two large-cap indices ($SPY and $QQQ) have consistently set record highs over the past month, but the Dow hasn’t notched a new high since November.
- $DIA remains tightly coiled beneath resistance at 45,000, representing the peaks from January and November. As Ross notes, a breakout would unlock the door to Dow 50k by year-end.




Every time there is a bull market in crypto, there is a new wrinkle, and this time that wrinkle is that you can buy exposure to altcoins in your brokerage account, through publicly traded companies that have gone all in on some cryptocurrencies.
The big picture: You might know that Tesla has some bitcoin and Strategy (formerly MicroStrategy) has all the bitcoin, but did you know that publicly traded companies are swiftly pivoting to buying and holding lots of other cryptocurrencies?
Catch up quick: There are crypto treasury firms, such as Sharplink Gaming for ether and DeFi Development Corp. for solana, and companies betting on extremely new cryptocurrencies, like the fitness firm Interactive Strength, which is buying the artificial intelligence coin from Fetch.ai.
- Many of these companies are issuing large amounts of new shares to sell to the public in order to buy more of their target cryptocurrency.
- The market has been rewarding them in a very meme stock-like way.
Case in point: Once upon a time, litecoin was seen as the silver to bitcoin's gold, but in recent years it hasn't had a strong reason to continue existing.
- MEI Pharma, a company devoted to developing cancer therapies, will buy $100 million worth of litecoin, funded through a private placement.
- The company, which lost money for the nine months ending in March, has typically traded in the $3 range for the last year. The deal fueled a 100% jump in price, with the stock now trading at $6.86.
- Butterfill calls the situation a "liquidity shift." There's plenty of money sloshing around, looking to go to work, some of it in a very meme stock mood, he notes.
- "At least in some ways bitcoin is regarded as an emerging store of value," he says. Other cryptocurrencies are more like tech stocks, if they are even that, he cautions.

jog on
duc